Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: Present and future directions

Current Opinion in Oncology

Volumn 16, Issue 4, 2004, Pages 385-390

  Starling, Naureen ^a   Cunningham, David ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Bevacizumab; Cetuximab; Colorectal cancer; Targeted treatments

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CYTOSTATIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PROTEIN P27; TRASTUZUMAB; VASCULOTROPIN;

ANGIOGENESIS; ASTHENIA; BLEEDING; CANCER THERAPY; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEVER; HUMAN; HYPERTENSION; NAUSEA; PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; SKIN TOXICITY; SWITZERLAND; THROMBOSIS; UNITED STATES;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; FORECASTING; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 3042769439     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000128278.15371.e4     Document Type: Review

References (36)

1. Gill S, Goldberg RM: First-line treatment strategies to improve survival in patients with advanced colorectal cancer. Drugs 2004, 64:27-44. A good overview of the current chemotherapeutic management of MCRC with particular reference to oxaliplatin and irinotecan.
2. Folkman J: Tumour angiogenesis: therapeutic implication. N Engl J Med 1971, 285:1182-1186.
3. Takebayashi Y, Akiyama S, Yamada K, et al.: Angiogenesis as an unfavourable prognostic factor in human colorectal carcinoma. Cancer 1996, 78:226-231.
4. Choi HJ, Hyun MS, Jung GJ, et al.: Tumour angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to the mode of metastasis and recurrence. Oncology 1998, 55:575-581.
5. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumourigenesis. Cell 1996, 86:353-364.
6. Ferrara N : Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002, 29(6 Suppl 6):10-14.
7. Millauer B, Longhi MP, Plate KH, et al.: Dominant-negative inhibition of flk-1 suppresses the growth of many tumour types in vivo. Cancer Res 1996, 56:1615-1620.
8. Takahashi Y, Kitadai Y, Bucana CD, et al.: Expression of vascular endothelial growth factor and its receptor KDR, correlates with vascularity, metastasis and proliferation of human colorectal cancer. Cancer Res 1995, 55:3964-3968.
9. Fernando NH, Hurwitz HI: Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol 2003, 30:39-50. An excellent review of angiogenesis, the role of VEGF, and the development of BV as an antiangiogenesis strategy, with particular emphasis on clinical application.
10. Warren RS, Yuan H, Matli MR, et al.: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995, 95:1789-1797.
11. Gordon MS, Margolin K, Talpaz M, et al.: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001, 19:843-850.
12. Margolin K, Gordon MS, Holmgren E, et al.: Phase Ib trial of intravenous recombinant humanised monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long term safety data. J Clin Oncol 2001, 19:851-856.
13. Willett CG, Boucher Y, Jain RK, et al.: Direct evidence that the VEGF-specific antibody bevacizumab has anti-vascular effects in human rectal cancer. Nat Med 2004, 10:145-147. An elegant phase I study undertaken in six patients, demonstrating directly that BV inhibits angiogenesis through assessment of vascular density, interstitial fluid pressure, and tumor perfusion.
14. Jain RK: Tumour angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 2002, 29(6 Suppl 6):3-9.
15. Kabbinavar F, Hurwitz H, Fehrenbacher L, et al.: Phase II, randomised trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21:60-65. An important small trial showing efficacy and safety data for BV in MCRC, after which phase III studies were undertaken.
16. Giantonio BJ, Levy D, O'Dwyer, et al.: Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as front-line therapy for advanced colorectal cancer (advCRC): updated results from the Eastern Cooperative Oncolgy Group (ECOG) Study E2200. Proc Am Soc Clin Oncol GI Symposium, 2004, Abstract No. 289. A phase II nonrandomized study of BV added to irinotecan-based chemotherapy in 92 patients with advanced CRC.
17. Hurwitz H, Fehrenbacher L, Cartwright T, et al.: Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL(irinotecan, 5 fluorouracil, leucovorin) as first line therapy in subjects with metastatic CRC. Proc Am Soc Clin Oncol 2003, 22: Abstract No. 3636. The pivotal phase III study demonstrating that the addition of BV to chemotherapy clearly improves response rate, survival, and time to progression in MCRC. These results led to approval of the drug by the United States Food and Drug Administration.
18. Hurwitz H, Fehrenbacher J, Hainsworth J, et al.: Bevacizumab in combination with 5-fluorouracil and leucovorin: a promising regimen for first-line metastatic colorectal cancer. Proc Am Soc Clin Oncol GI Symposium, 2004: Abstract No. 286.
19. Gray R, Giantonio BJ, O'Dwyer PJ, et al.: The safety of adding angiogenesis inhibition into treatment for colorectal, breast and lung cancer: the Eastern Cooperative Oncology Group's experience with bevacizumab. Proc Am Soc Clin Oncol. 2003, 22: Abstract No. 206. An important assessment of safety with the use of BV with particular reference to hypertension, thrombotic complications, bleeding, and proteinuria.
20. Yarden Y, Sliwkowski MX: Untangling the ErbB signaling network. Nature 2001, 2:127-137.
21. Mendleson J: Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002, 20:1s-13s.
22. Ciardiello F, Tortora G: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001, 7:2958-2970.
23. Goldstein NS, Armin M: Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 2001, 92:1331-1346.
24. Nicholson RI, Gee JMW, Harper ME: EGFR and cancer prognosis. Eur J Cancer 2001, 37:S9-S15.
25. Prewtt MC, Hooper AT, Bassi R, et al.: Enhanced antitumour activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumour xenografts. Clin Cancer Res 2002, 8:994-1003.
26. Ciardiello F, Bianco R, Damiano V, et al.: Antitumour activity of sequential treatment with topetecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999, 5:909-916.
27. Baselga J, Pfister D, Cooper MR, et al.: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000, 18:904-914.
28. Raoul JL, Van Laethem JL, Mitry E, et al.: Phase II study of cetuximab combined with FOLFIRI (bi-weekly irinotecan plus infusionla 5-FU and folinic acid (FA) in patients (pts) with metastatic, epidermal growth factor receptor (EGFR)-expressing colorectal cancer (CRC). Eur J Cancer 2003, 1:S89 (abstract no. 289). A small nonrandomized trial demonstrating the safety and potential efficacy of cetuximab with irinotecan and infusional 5-FU in chemonaive patients before the undertaking of larger studies in this particular patient population.
29. Rosenberg AH, Loehrer PJ, Needle MN, et al.: Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil and leucovorin in colorectal cancer that expresses the epidermal growth factor receptor. Proc Am Soc Clin Oncol 2002, Abstract No. 536.
30. Schoffski P, Lutz C-H, Folprecht G, et al.: Cetuximab (C225, Erbitux) in combination with irinotecan, infusional 5-flurouracil and folinic acid is safe and active in patients with metastatic colorectal cancer expressing epidermal growth factor receptor: results of a phase I study. Eur J Cancer 2002, 38(suppl 7):S148-S149 (abstract no. 495).
31. Saltz L, Rubin MS, Hochester HS, et al.: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorecta) cancer that expresses epidermal growth factor receptor. Proc Am Soc Clin Oncol 2001, 20: Abstract No. 7.
32. Saltz L, Meropol NJ, Loehrer PJ, et al.: Single agent IMC-C225 (Erbitux TM) has activity in CPT-11 refractory colorectal cancer that expresses the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2002, 21:Abstract No. 504
33. Saltz L, Kies M, Abbruzzese N, et al.: The presence and intensity of the cetuximab induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol. 2003, 22: Abstract No. 817. An interesting retrospective analysis correlating the presence of skin rash with survival and efficacy across four phase II studies with oetuximab in tumor types, including colorectal.
34. Cunningham D, Humblet Y, Cutsem AV, et al.: Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2003, 22: Abstract No. 1012. The pivotal randomized phase II study clearly demonstrating the efficacy and safety of cetuximab either alone or in combination with irinotecan, which has provided the impetus for further studies to define the use of this drug and for a license being granted in Switzerland.
35. Kim ES, Vokes EE, Kies MS: Cetuximab in cancers of the lung and head and neck. Semin Oncol 2004, 31(1 Suppl 1):61-67. A thorough review of the use of cetuximab in cancers of the aerodigestive tract with reference to combination with radiotherapy as a treatment modality.
36. Mendelson J, Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003, 21:2787-2799. An excellent review of the mechanism of action of cetuximab, potential therapeutic strategies to exploit EGFR, and the challenges of developing anti-EGFR agents for use in malignant disease.